Amphastar Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amphastar Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Amphastar Pharmaceuticals Inc achieved a return on average assets (ROA) of 4.54 % in its second quarter of 2026, which is below Amphastar Pharmaceuticals Inc 's average return on assets, which stands at 4.84%.

ROA fell compared to the first quarter of 2026, despite the net income growth of 372.71% from the first quarter of 2026.

However, within the Healthcare sector 159 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 1201 to 1215.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	22.01 %	1.18 %	3.18 %	7.83 %	-3.88 %
Y / Y Net Income Change	-2.2 %	-74.61 %	-35.65 %	-57.09 %	-18.23 %
Net Income (TTM) in million	79	79	98	112	135
Return On Assets (TTM)	4.54 %	4.83 %	6 %	6.88 %	8.46 %
AMPH's Total Ranking	# 1215	# 1201	# 894	# 745	# 688
Total Assets (TTM) in million	1,972	1,648	1,629	1,666	1,617
Seq. Total Assets Change	19.67 %	1.16 %	-2.22 %	3.07 %	-0.76 %
Seq. Net Income Change	372.71 %	-73.72 %	40.8 %	-44.09 %	22.72 %

AMPH's 5 Years Annual ROA >> Back to AMPH Management Effectiveness >> Compare AMPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 60
Sector	# 160
Overall	# 1237

Return On Assets Statistics
High	Average	Low
13.36 %	4.84 %	-3.84 %
(Jun 30 2022)		(Jun 30 2015)

Financial Statements
Amphastar Pharmaceuticals Inc 's Assets	$ 1,972 million	AMPH's Balance sheet
Amphastar Pharmaceuticals Inc 's Income	$ 30 million	Quarterly AMPH's Income Statement
AMPH's Income by Division		See AMPH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	3.18 %	4.28 %	104.01 %	10.54 %	6.38 %
Total Assets in million	1,629	1,579	1,514	742	672
Y / Y Net Income Change	-38.51 %	15.98 %	50.51 %	44.37 %	5670.37 %
Net Income in million	98	160	138	91	63
Annual Return On Assets	6.02 %	10.1 %	9.08 %	12.31 %	9.43 %

AMPH's 5 Years Annual ROA >> Back to AMPH Management Effectiveness >> Compare AMPH ROA to its Competitors

Comment on AMPH's ROA in the fiscal year ending 2025

In the fiscal year 2025 Amphastar Pharmaceuticals Inc 's ROA decreased compared to previous year to 6.02 %, due to deterioration of net income -38.51 % to $98.09 million, from $159.52 million a year ago, as AMPH's assets were $1,629.30 million.

More Return On Assets Ratios
AMPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMPH's Competitors
Subscribers only: Roa for Amphastar Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AMPH's Customers

You may also want to know
AMPH's Roi	AMPH's Inventory Turnover Ratio	AMPH's Growth Rates	AMPH's Dividend Comparisons
	AMPH's Profitability Ratios	AMPH's Asset Turnover Ratio	AMPH's Dividend Growth
AMPH's Roe	AMPH's Valuation Ratios	AMPH's Financial Strength Ratios	AMPH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Eton Pharmaceuticals Inc	12.37 %
Nephros Inc	12.30 %
Msa Safety Inc	12.23 %
Strata Critical Medical Inc	12.18 %
Insulet Corporation	12.13 %
Lantheus Holdings Inc	11.89 %
Ligand Pharmaceuticals Incorporated	11.68 %
Theravance Biopharma inc	11.68 %
Carlisle Companies Incorporated	11.62 %
Encompass Health Corporation	11.60 %
Protagonist Therapeutics inc	11.02 %
Agilent Technologies inc	10.97 %
Prestige Consumer Healthcare Inc	10.90 %
Lemaitre Vascular Inc	10.90 %
Ufp Technologies Inc	10.85 %
Progyny Inc	10.66 %
Regeneron Pharmaceuticals Inc	10.60 %
Johnson and Johnson	10.60 %
Tenet Healthcare Corp	10.49 %
Bristol myers Squibb Company	10.27 %
Solventum Corporation	10.13 %
Globus Medical Inc	10.04 %
Universal Health Services Inc	9.92 %
Entrada Therapeutics Inc	9.51 %
Amgen Inc	9.48 %
National Healthcare Corp	9.28 %
Tactile Systems Technology Inc	9.17 %
Bioventus Inc	9.08 %
Infusystem Holdings Inc	8.63 %
Penumbra Inc	8.63 %

Date modified: 2026-09-08T01:08:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.